StockData
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. (TCRX) stock

TCRXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/3089% below fair value
$0.15−0.00 (-1.72%)

Close on Nov 18, 2026Market cap $10.06MP/E –Yield –

TScan Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

TScan Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$120.54M. For fiscal 2025 it was -$135.81M. The highest annual figure on record is -$26.23M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$135.81M–
FY2024Dec 31, 2024-$134.82M–
FY2023Dec 31, 2023-$93.46M–
FY2022Dec 31, 2022-$66.64M–
FY2021Dec 31, 2021-$48.64M–
FY2020Dec 31, 2020-$26.23M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$30.49M–
Q1 FY2026Mar 31, 2026-$29.14M–
Q4 FY2025Dec 31, 2025-$23.86M–
Q3 FY2025Sep 30, 2025-$37.05M–
Q2 FY2025Jun 30, 2025-$38.65M–
Q1 FY2025Mar 31, 2025-$36.25M–
Q4 FY2024Dec 31, 2024-$36.71M–
Q3 FY2024Sep 30, 2024-$32.62M–
Q2 FY2024Jun 30, 2024-$34.11M–
Q1 FY2024Mar 31, 2024-$31.37M–
Q4 FY2023Dec 31, 2023-$21.36M–
Q3 FY2023Sep 30, 2023-$24.75M–
Q2 FY2023Jun 30, 2023-$24.61M–
Q1 FY2023Mar 31, 2023-$22.74M–
Q4 FY2022Dec 31, 2022-$18.65M–
Q3 FY2022Sep 30, 2022-$16.58M–
Q2 FY2022Jun 30, 2022-$15.25M–
Q1 FY2022Mar 31, 2022-$16.16M–
Q4 FY2021Dec 31, 2021-$14.20M–
Q3 FY2021Sep 30, 2021-$15.84M–
Q2 FY2021Jun 30, 2021-$10.68M–
Q1 FY2021Mar 31, 2021-$7.92M–
Q4 FY2020Dec 31, 2020-$7.81M–
Q3 FY2020Sep 30, 2020-$7.17M–
Q2 FY2020Jun 30, 2020-$5.62M–

More TScan Therapeutics figures

See a number that looks wrong?